What belongs inside the container closure integrity assessment?
Identify the complete containment boundary and the interfaces that can affect it. The cartridge barrel, stopper, closure and relevant connections need a controlled configuration record before an integrity report can be interpreted.
A reusable metal body can protect and actuate a cartridge without itself forming the sterile barrier. Conversely, a component that appears small can be central to sealing. Start a review with a drawing or component map that identifies the barrier and separates it from the external housing. Record materials, suppliers, revisions and the assembled state evaluated. Ask whether the report applies before assembly, after assembly or after specified handling conditions. A photograph may clarify geometry but cannot establish a leak threshold or barrier performance. For a multi-use presentation, the responsible team must also determine which lifecycle states need assessment. Keep the method rationale, sample identity and acceptance basis in the same evidence record.
Does sterility testing answer the same question as integrity testing?
No: a sterility test and a container-integrity assessment address different evidence questions. Neither a passing sample result nor the absence of visible leakage establishes that every proposed configuration maintains its containment boundary throughout its intended lifecycle.
FDA’s integrity-testing guidance discusses the use of suitable integrity methods within a stability protocol; that context should not be converted into a blanket replacement rule for every sterility activity. USP <1207> provides a package-integrity framework, with method selection and validation addressed in related chapters. These references identify a review structure, not a universal instrument or acceptance limit for any cartridge. The project team should justify the method against the actual system, its ability to detect relevant defects and the intended lifecycle conditions. Procurement should request the report scope and responsible reviewer rather than prescribe an unsupported numerical limit. A supplier certificate without the underlying configuration reference leaves that decision unresolved.
Which evidence should an RFQ request?
Request the system identification, method rationale, acceptance basis, lifecycle conditions and the report owner. A useful response distinguishes published reference information from test evidence that applies to the exact proposed assembly.
Ask the supplier to identify which entity owns the container and filling process, which entity assembles the device and who approves the integrity evidence. Specify the sample purpose before comparing test quotations. If a stopper or closure changes, determine whether earlier results remain relevant rather than carrying a previous pass into the new record. Include the proposed shipping, storage and use states as inputs for technical review, without inventing a standard set of conditions. Confidential reports can be handled through an agreed document-review route. A purchasing decision should state what was reviewed, what remains open and what next stage is authorized. Appearance approval and barrier qualification should remain separate decisions.
Supplier evidence decision record
| Review area | Record to request | Purchasing question |
|---|---|---|
| System | Cartridge, stopper, closure and assembly revisions | Which exact barrier was evaluated? |
| Method | Method identifier, validation scope and detection rationale | Why is the method suitable for this system? |
| Lifecycle | States and conditions represented in the assessment | What remains outside the report scope? |
| Acceptance | Justified criteria and responsible approval | Who accepts the result and any deviations? |
Questions buyers should resolve
Confirm which configuration and intended decision the evidence supports. Keep unknown inputs, report limitations and responsible reviewers visible before accepting a supplier statement.
Does an empty pen housing need the same integrity claim as a filled cartridge?
The claim should follow the containment boundary. A housing and a filled container have different functions; identify which components form the barrier and which evidence applies to them.
Can a visual inspection replace a configuration-specific integrity assessment?
A visual check can identify visible damage but does not by itself establish barrier performance. The responsible team must select and justify the appropriate assessment for the actual system.
What changes can trigger another integrity review?
Changes to the container, stopper, closure, assembly or relevant lifecycle conditions can affect the evidence scope. Document the change and assess its impact before reusing an earlier report.
Sources and applicability
- USP <1207>: Package Integrity Evaluation—Sterile Products (public preview; full chapter requires access) · Reference checked 23 October 2026
- FDA: Integrity testing as a component of a stability protocol · Reference checked 23 October 2026
- FDA: Container Closure Systems for Packaging Human Drugs and Biologics — final guidance, 1999 · Reference checked 23 October 2026
This article combines public reference scopes with original procurement analysis. It is not a laboratory protocol, a claim of product conformity or evidence that Hytanbio-Tech performed the illustrated tests. The responsible technical and regulatory teams determine the applicable requirements and assessment plan.
Source-status note: FDA lists the 1999 packaging guidance as final and an August 2026 container-closure guidance as draft, not for implementation. A draft should not be presented as a final requirement.